标题
Ceftolozane/tazobactam: place in therapy
作者
关键词
-
出版物
Expert Review of Anti-Infective Therapy
Volume 16, Issue 4, Pages 307-320
出版商
Informa UK Limited
发表日期
2018-03-01
DOI
10.1080/14787210.2018.1447381
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany
- (2018) Harald Seifert et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa : clinical and microbiological outcomes
- (2018) B. Dietl et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013–2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility
- (2018) Dee Shortridge et al. Microbial Drug Resistance
- Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae to slow the emergence of carbapenem-resistant Enterobacteriaceae
- (2017) Richard R. Watkins et al. Expert Review of Anti-Infective Therapy
- Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam
- (2017) Marc Xipell et al. Future Microbiology
- Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant
- (2017) Maddalena Peghin et al. INFECTION
- Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy
- (2017) Daniele Roberto Giacobbe et al. INFECTION
- Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach
- (2017) Matteo Bassetti et al. INTENSIVE CARE MEDICINE
- Use of ceftolozane/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa
- (2017) Aurélien Dinh et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model
- (2017) Rachel L. Soon et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane/tazobactam and comparison of different susceptibility testing methods
- (2017) Frieder Schaumburg et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers
- (2017) Tommaso Giani et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L
- (2017) Senthil Natesan et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy
- (2017) Ivan Gentile et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15)
- (2017) Michael A. Pfaller et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of ceftolozane/tazobactam against surveillance and ‘problem’ Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles
- (2017) David M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
- (2017) Courtney Davis et al. BMJ-British Medical Journal
- Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
- (2017) Courtney Davis et al. BMJ-British Medical Journal
- Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam
- (2017) Nadia Castaldo et al. Journal of Global Antimicrobial Resistance
- Ceftolozane–tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013–2015)
- (2017) M.A. Pfaller et al. Journal of Global Antimicrobial Resistance
- Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK
- (2017) Vimalanand Prabhu et al. JOURNAL OF MEDICAL ECONOMICS
- Real-world Analysis of Prescribing Patterns and Susceptibility of Ceftolozane/Tazobactam (C/T) Treatment using an Electronic Medical Record (EMR) Database in the United States
- (2017) Jason M Pogue et al. Open Forum Infectious Diseases
- Real-world Evaluation of Ceftolozane/Tazobactam (C/T) Use and Clinical Outcomes at an Academic Medical Center in Las Vegas
- (2017) Kimberly D Leuthner et al. Open Forum Infectious Diseases
- Physical compatibility of ceftolozane–tazobactam with selected i.v. drugs during simulated Y-site administration
- (2016) Abrar K. Thabit et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam–β-Lactamase Inhibitor Combinations
- (2016) Rachel L. Soon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae
- (2016) Belén Gutiérrez-Gutiérrez et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study
- (2016) Benjamin Miller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation
- (2016) Marguerite L. Monogue et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections
- (2016) Juan José Castón et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa in the planktonic and biofilm states
- (2016) Antonio L. Velez Perez et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam
- (2016) Alberto Hernández-Tejedor et al. INFECTION
- Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration
- (2016) Joseph L. Kuti et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Antimicrobial Resistance
- (2016) Hilary D. Marston et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial
- (2016) Jennifer A. Huntington et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae : a pooled analysis of Phase 3 clinical trials
- (2016) Myra W. Popejoy et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Comparison of Etest to Broth Microdilution for Testing of Susceptibility of Pseudomonas aeruginosa to Ceftolozane-Tazobactam
- (2016) Lauren K. Flynt et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient
- (2016) Samuel L. Aitken et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy
- (2016) Derek N. Bremmer et al. PHARMACOTHERAPY
- Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-ResistantPseudomonas aeruginosa
- (2016) Stephen B. Vickery et al. PHARMACOTHERAPY
- Ceftolozane/Tazobactam
- (2015) Allana J. Sucher et al. ANNALS OF PHARMACOTHERAPY
- In VitroActivity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI Study
- (2015) Eliana S. Armstrong et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftolozane-Tazobactam Activity against Phylogenetically Diverse Clostridium difficile Strains
- (2015) Mark D. Gonzalez et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins
- (2015) M. Berrazeg et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacodynamics of Ceftolozane plus Tazobactam Studied in anIn VitroPharmacokinetic Model of Infection
- (2015) Alasdair P. MacGowan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-ResistantPseudomonas aeruginosa: Table 1.
- (2015) Michael S. Gelfand et al. CLINICAL INFECTIOUS DISEASES
- Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
- (2015) Joseph Solomkin et al. CLINICAL INFECTIOUS DISEASES
- Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case–control–control study
- (2015) D.R. Giacobbe et al. CLINICAL MICROBIOLOGY AND INFECTION
- Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis
- (2015) Joseph L. Kuti et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae
- (2015) Hadas Ofer-Friedman et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections
- (2015) Jordan L. Liscio et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia
- (2015) Alan J. Xiao et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
- (2015) Florian M Wagenlehner et al. LANCET
- Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination
- (2015) Jonathan C. Cho et al. PHARMACOTHERAPY
- Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival
- (2015) Chul Kim et al. JAMA Internal Medicine
- Mutation-Driven β-Lactam Resistance Mechanisms among Contemporary Ceftazidime-Nonsusceptible Pseudomonas aeruginosa Isolates from U.S. Hospitals
- (2014) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Impact of Renal Function on the Pharmacokinetics and Safety of Ceftolozane-Tazobactam
- (2014) Myra Wooley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multicenter, Double-Blind, Randomized, Phase II Trial To Assess the Safety and Efficacy of Ceftolozane-Tazobactam plus Metronidazole Compared with Meropenem in Adult Patients with Complicated Intra-Abdominal Infections
- (2014) Christopher Lucasti et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC
- (2014) Gabriel Cabot et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Relationship between Ceftolozane-Tazobactam Exposure and Selection for Pseudomonas aeruginosa Resistance in a Hollow-Fiber Infection Model
- (2014) Brian D. VanScoy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections
- (2014) Gurudatt Chandorkar et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in anIn VitroInfection Model
- (2013) Brian VanScoy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane
- (2013) Brian VanScoy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli
- (2013) George G. Zhanel et al. DRUGS
- Pan-β-Lactam Resistance Development in Pseudomonas aeruginosa Clinical Strains: Molecular Mechanisms, Penicillin-Binding Protein Profiles, and Binding Affinities
- (2012) Bartolomé Moyá et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VivoActivities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic Mice
- (2012) W. A. Craig et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects
- (2012) G. Chandorkar et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes
- (2011) Helio S. Sader et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality
- (2011) M. TUMBARELLO et al. EPIDEMIOLOGY AND INFECTION
- Affinity of the New Cephalosporin CXA-101 to Penicillin-Binding Proteins of Pseudomonas aeruginosa
- (2010) B. Moya et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of a New Cephalosporin, CXA-101 (FR264205), against -Lactam-Resistant Pseudomonas aeruginosa Mutants Selected In Vitro and after Antipseudomonal Treatment of Intensive Care Unit Patients
- (2010) B. Moya et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients
- (2010) L. Zamorano et al. CLINICAL MICROBIOLOGY AND INFECTION
- Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus -lactamase-producing Enterobacteriaceae
- (2010) D. M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1
- (2010) E. Riera et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern
- (2008) Johann DD Pitout et al. LANCET INFECTIOUS DISEASES
- Structural requirements for the stability of novel cephalosporins to AmpC β-lactamase based on 3D-structure
- (2007) Kenji Murano et al. BIOORGANIC & MEDICINAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More